Cannabis is becoming increasingly available nationwide. Cannabidiol (CBD), a non-psychoactive cannabinoid, has become sought after as an alternative to delta-9-tetrahydrocannabinol (THC) as it appears to provide a number of therapeutic benefits without the alteration of consciousness associated with THC. A number of surveys of cannabis users have suggested that pain is the most frequent condition for which patients seek medicinal cannabis. States where medicinal cannabis is available are reporting a decline in opiate use and opiate-related deaths. It remains unknown at this time which cannabinoid is most effective and/or necessary for analgesia and relief of other symptoms. Patients query their physicians regarding what ratio of CBD to THC they need for pain, sleep, migraines, etc for which no answers exist as there is no available data. Physicians often recommend that patients ask the dispensary workers what would be the best product to suit their needs. Three BraveNet sites in locations where medicinal cannabis is available will pilot a cross sectional survey to assess use of CBD by patients seen in their clinics. As a comparator, we will also administer the same survey, paper or on-line, to clients at a dispensary nearby the clinic. Patients and dispensary clients will describe what CBD products they use, modes of delivery, what conditions they are treating, their perception of effectiveness and whether they have altered their use of any prescription medications, including opiates. Dispensary workers will have the opportunity to describe what CBD products they recommend for which conditions and why. We hypothesize that most patients will be using CBD for pain. The results of this cross-sectional observational pilot will be used to inform the design of a follow on trial which will prospectively investigate CBD in a condition for which it appears to have the most potential for benefit.
|Effective start/end date||6/1/18 → 5/31/19|
- Albert Einstein College of Medicine, Inc. (3A1543)